xPloration is OmniAb’s proprietary, innovative, high-throughput single B-cell screening platform that leverages machine learning and artificial intelligence.
“xPloration has been a core part of our company’s discovery workflow for several years and our partners are increasingly recognizing its substantial value. Following multiple inbound inquiries and extensive testing and validation, the instrument and proprietary single-use consumables are now ready for sale to current partners for use within their own laboratories,” said Matt Foehr, Chief Executive Officer of OmniAb.
“xPloration represents a significant advancement in single B-cell screening and antibody discovery. It provides important advantages in the speed and quality of throughput due to its superior processing speed, exceptional hit recovery, unparalleled ease-of-use and reliability,” he added. “This launch to our growing base of nearly 100 partners via the xPloration Partner Access Program increases the reach of our business and also adds new revenue streams to OmniAb, while furthering our mission of pushing the frontiers of discovery technologies.”
xPloration leverages custom chips with approximately 1.5 million microcapillaries to isolate individual B-cells. With a robust, user-friendly design and rapid instrument run times of approximately 1.5 hours, xPloration meets the evolving discovery needs of the biopharmaceutical industry. It excels in screening and cell recovery, outperforming other spatial separation techniques and enables the discovery of rare cells that may be missed by competing systems. The instrument’s laser-based recovery process enhances discovery efficiency through advanced functional screening assays and large-scale repertoire mining. Additionally, its fluidics-free system and simple guided interface facilitates setup with minimal calibrations while boosting ease of use and reliability.
“Mining primary B-cells from immunized animals is a major challenge in therapeutic antibody discovery. Traditional methods, like hybridoma or FACS-based screening, limit antibody diversity, take weeks to run and/or are restricted to simple soluble antigens. In contrast, our xPloration platform processes millions of single B-cells and recovers thousands of antibody variants within hours, delivering superior screening and cell recovery capabilities while facilitating workflow flexibility,” added Bob Chen, Ph.D., OmniAb’s Vice President of Discovery Systems.
The capabilities of xPloration will be showcased in two separate presentations at the 21st Annual PEGS Boston Summit, taking place May 12-16, 2025, at the Omni Boston Hotel at the Seaport. Dr. Chen will present case studies in a presentation titled “xPloration: Simplifying Deep Antibody Mining for Maximum Impact” on Tuesday, May 13th at 12:15 p.m. Eastern time. Dr. Chen’s slides will be available in the Scientific Presentations section of OmniAb’s website shortly after the presentation.
John Kenney, Ph.D., President & Co-founder of Antibody Solutions, will deliver a lunchtime presentation titled “How to Get Your B-Cells on the A-List: Generating Relevant Diversity, Affinity, and Specificity from an Immune Repertoire” on Wednesday, May 14th at 12:00 p.m. Eastern time. Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, is the first external user of xPloration technology.
About OmniAb®:
OmniAb licenses cutting edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is something we call Biological Intelligence™, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B-cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, is used to identify fully-human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions. Our business model aligns scientific and economic interests of our partners through structured agreements that generally include upfront/access fees, service revenue, milestones and royalties on commercial sales.
For more information, please visit www.omniab.com
